Skip to content
value.today
Lucid Diagnostics Inc. logo

Lucid Diagnostics Inc.

LUCD
$89 Mmarket cap on Oct 30, 2026+43.5% since Jan 2024
Compare
World rank
#19,162
Revenue
$5 M
For year ending December-2025
Net income
$-58 M
-1231.6% margin
SEC filing
Employees
82
As of March 23, 2026
SEC filing

Lucid Diagnostics Inc. in brief

Lucid Diagnostics Inc. is a listed company in the Healthcare sector, based in New York, New York, USA. Its market value was $89 M on 30 October 2026, which makes it the 19,162nd largest listed company in the world and the 3,576th largest in the USA on this site. In the year to December 2025 it had sales of $5 M and a net loss of $58 M. It employs about 82 people and Lishan Aklog is its chief executive. Its shares trade under the symbol LUCD (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Lucid Diagnostics Inc.

Lucid Diagnostics is a commercial-stage cancer prevention medical diagnostics technology company. Lucid is focused on the millions of patients with gastroesophageal reflux disease, also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma.

We believe that our flagship product, the EsoGuard Esophageal DNA Test, performed on samples collected with the EsoCheck Esophageal Cell Collection Device, constitutes the first and only commercially available diagnostic test capable of serving as a widespread testing tool with the goal of preventing EAC deaths, through early detection of esophageal precancer in at-risk GERD patients.

From the company's annual report filed with the US SEC: read the report

Lucid Diagnostics Inc. timeline

3 events, 2020–2025
  1. 2020
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2021
  4. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 15 October 2021; shares registered for exchange trading on 12 October 2021.
  5. 2025
  6. 💰
    Record revenue of $5 million
    FY2025, the highest of the 5 years on record.

Events of Lucid Diagnostics Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$53 M$106 M$160 M$213 M2023202420252026

World rank over time

▲ up 607 places since 2022
2022-01-07: #19810#19,81020222022-12-25: #24727#24,72720222023-07-30: #24571#24,57120232024-01-05: #23903#23,90320242026-03-08: #9044#9,04420262026-08-01: #15455#15,45520262026-10-14: #17965#17,96520262026-10-30: #19203#19,2032026

Rank in USA: #4,006 (Jan 2022) · #4,712 (Dec 2022) · #4,642 (Jul 2023) · #3,955 (Jan 2024) · #1,723 (Mar 2026) · #3,115 (Aug 2026) · #3,367 (Oct 2026) · #3,580 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
16.4×
Price / book
8.1×
Free cash flow yield
-52.4%
Net margin (TTM)
-892.3%
Operating margin
-1053.9%
Return on equity
-443.7%
Liabilities / assets
73.0%
Revenue growth
+8.3%
R&D / revenue
120.6%
Revenue per employee
$57 K
Profit per employee
$-707 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2020: revenue —, net income $-8M—FY20Fiscal year ending Dec 2021: revenue $1M, net income $-28M$1MFY21Fiscal year ending Dec 2022: revenue $0M, net income $-56M$0MFY22Fiscal year ending Dec 2023: revenue $2M, net income $-53M$2MFY23Fiscal year ending Dec 2024: revenue $4M, net income $-46M$4MFY24Fiscal year ending Dec 2025: revenue $5M, net income $-58M$5MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$5M+8.3%$-50M$-58M-1231.6%
Dec 2024$4M+79.0%$-46M$-46M-1046.7%
Dec 2023$2M+539.5%$-48M$-53M-2167.5%
Dec 2022$0M-24.0%$-56M$-56M-14781.6%
Dec 2021$1M—$-27M$-28M-5616.0%
Dec 2020——$-8M$-8M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-46M$0M$-47M——
Dec 2024$-44M$0M$-44M$-1.05—
Dec 2023$-33M——$-1.26—
Dec 2022$-30M$3M$-33M$-1.55—
Dec 2021$-18M$1M$-19M$-1.51—
Dec 2020$-6M——$-0.59—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$5M
Net income, trailing 12 months
$-49M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $1M, net income $-12M$1MDec ’24Three months to Mar 2025: revenue $1M, net income $-27M$1MMar ’25Three months to Jun 2025: revenue $1M, net income $-4M$1MJun ’25Three months to Sep 2025: revenue $1M, net income $-10M$1MSep ’25Three months to Dec 2025 (from the annual report): revenue $2M, net income $-16M$2MDec ’25Three months to Mar 2026: revenue $1M, net income $-14M$1MMar ’26Three months to Jun 2026: revenue $1M, net income $-12M$1MJun ’26Three months to Sep 2026: revenue $1M, net income $-7M$1MSep ’26

Latest quarter to Sep 2026: revenue $1M (-0.8% on a year earlier), net income $-7M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Lucid Diagnostics Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$5 M
Operating income
$-50 M
Net income
$-58 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$40 M
Total liabilities
$30 M
Total equity
$11 M

As of December-2025

Top 100 institutional investors in Lucid Diagnostics Inc.#

As of Sep 30, 2026
116 institutions held 60.3 M shares (about 29.1% of the shares outstanding) on Sep 30, 2026. The ten largest hold 23.0%. Source: SEC Form 13F filings, filed through Nov 18, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Lucid Diagnostics Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1BlackRock, Inc.8,387,879+14,762 (+0.18%)4.05%$6 MNov 13, 2026
2Alyeska Investment Group, L.P.7,970,115-886,729 (-10.01%)3.85%$6 MNov 16, 2026
3Vanguard Capital Management LLC6,045,227-511,117 (-7.80%)2.92%$5 MNov 13, 2026
4Two Seas Capital LP6,000,0000 (0.00%)2.90%$5 MOct 6, 2026
5Aberdeen Group plc4,419,935+596,938 (+15.61%)2.14%$3 MNov 10, 2026
6Masters Capital Management LLC4,000,0000 (0.00%)1.93%$3 MNov 16, 2026
7Geode Capital Management, LLC3,566,004-223,944 (-5.91%)1.72%$3 MNov 6, 2026
8Wells Fargo & Company/mn2,535,899+468,853 (+22.68%)1.23%$2 MNov 16, 2026
9State Street Corp2,442,220+4,883 (+0.20%)1.18%$2 MNov 12, 2026
10First Manhattan Co. LLC.2,188,5500 (0.00%)1.06%$2 MNov 16, 2026
11Northern Trust Corp1,236,016+16,137 (+1.32%)0.60%$1 MNov 16, 2026
12UBS Group AG1,144,954+299,640 (+35.45%)0.55%$1 MNov 10, 2026
13Perkins Capital Management Inc1,125,0000 (0.00%)0.54%$1 MNov 2, 2026
14Vanguard Portfolio Management LLC1,066,566+44,304 (+4.33%)0.52%$1 MNov 13, 2026
15Vanguard Fiduciary Trust Co1,002,094-66,015 (-6.18%)0.48%$1 MNov 13, 2026
16Citadel Advisors LLC644,559+608,197 (+1672.62%)0.31%$0 MNov 16, 2026
17Raymond James Financial Inc577,3810 (0.00%)0.28%$0 MNov 12, 2026
18Lido Advisors, LLC446,711-28 (-0.01%)0.22%$0 MNov 4, 2026
19Charles Schwab Investment Management Inc407,000+81,688 (+25.11%)0.20%$0 MNov 16, 2026
20Rothschild Capital Partners, LLC372,340New0.18%$0 MNov 16, 2026
21XTX Topco Ltd342,566New0.17%$0 MNov 16, 2026
22XML Financial, LLC323,1950 (0.00%)0.16%$0 MOct 29, 2026
23Bank of New York Mellon Corp313,474+11,771 (+3.90%)0.15%$0 MNov 5, 2026
24Nuveen, LLC301,157+106,092 (+54.39%)0.15%$0 MNov 10, 2026
25Bank Of Montreal /can/289,9360 (0.00%)0.14%$0 MNov 9, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Lucid Diagnostics Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Focus Partners Wealth183,708+35,003 (+23.54%)0.09%$0 MNov 12, 2026
27Tripletail Wealth Management, LLC183,4170 (0.00%)0.09%$0 MNov 16, 2026
28Squarepoint Ops LLC169,704New0.08%$0 MNov 9, 2026
29Bank Of America Corp /de/162,450+65,674 (+67.86%)0.08%$0 MNov 16, 2026
30Morgan Stanley142,094+76,351 (+116.14%)0.07%$0 MNov 13, 2026
31Rhumbline Advisers140,891+56,808 (+67.56%)0.07%$0 MNov 10, 2026
32Deutsche Bank AG\129,876-18,185 (-12.28%)0.06%$0 MNov 6, 2026
33LPL Financial LLC129,443-3,712 (-2.79%)0.06%$0 MNov 6, 2026
34Price T Rowe Associates Inc /MD/121,9520 (0.00%)0.06%$0 MNov 16, 2026
35AQR Capital Management LLC119,525-603,675 (-83.47%)0.06%$0 MNov 16, 2026
36Invesco Ltd.92,610+9,856 (+11.91%)0.04%$0 MNov 12, 2026
37Sequoia Financial Advisors, LLC92,140-10 (-0.01%)0.04%$0 MNov 13, 2026
38Jpmorgan Chase & Co74,382+11,607 (+18.49%)0.04%$0 MNov 12, 2026
39MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.72,152+3,681 (+5.38%)0.03%$0 MNov 16, 2026
40Corient Private Wealth LP64,501+54,473 (+543.21%)0.03%$0 MNov 16, 2026
41Barclays PLC61,773+35,183 (+132.32%)0.03%$0 MNov 6, 2026
42New York State Common Retirement Fund58,7000 (0.00%)0.03%$0 MNov 17, 2026
43Traphagen Investment Advisors LLC58,5900 (0.00%)0.03%$0 MOct 14, 2026
44Virtu Financial LLC56,249New0.03%$0 MNov 17, 2026
45Susquehanna International Group, LLP53,881+37,763 (+234.29%)0.03%$0 MNov 16, 2026
46MML Investors Services, LLC50,0000 (0.00%)0.02%$0 MNov 13, 2026
47Alliancebernstein L.P.47,2000 (0.00%)0.02%$0 MNov 16, 2026
48Sargent Investment Group, LLC45,000-20,000 (-30.77%)0.02%$0 MNov 13, 2026
49Royal Bank Of Canada44,607+20,170 (+82.54%)0.02%$0 MNov 16, 2026
50Magnus Financial Group LLC40,900-14,500 (-26.17%)0.02%$0 MOct 21, 2026
51Vanguard Global Advisers, LLC40,457+15,557 (+62.48%)0.02%$0 MNov 13, 2026
52Oppenheimer & Co Inc40,000+10,000 (+33.33%)0.02%$0 MOct 26, 2026
53StoneX Group Inc.39,748New0.02%$0 MNov 3, 2026
54BNP Paribas Financial Markets37,539+14,914 (+65.92%)0.02%$0 MNov 12, 2026
55Pine Valley Investments Ltd Liability Co36,4830 (0.00%)0.02%$0 MNov 9, 2026
56Russell Investments Group, Ltd.36,355-1,615,433 (-97.80%)0.02%$0 MNov 6, 2026
57R Squared Ltd34,341+3,754 (+12.27%)0.02%$0 MNov 6, 2026
58Police & Firemen's Retirement System of New Jersey30,7390 (0.00%)0.01%$0 MNov 9, 2026
59Americana Partners, LLC26,4270 (0.00%)0.01%$0 MOct 28, 2026
60Sax Wealth Advisors, LLC25,287New0.01%$0 MOct 13, 2026
61Two Sigma Securities, LLC22,854-17,067 (-42.75%)0.01%$0 MNov 16, 2026
62Prudential Financial Inc22,4350 (0.00%)0.01%$0 MNov 16, 2026
63Scratch Capital LLC20,9940 (0.00%)0.01%$0 MNov 2, 2026
64Gabelli Funds LLC19,5000 (0.00%)0.01%$0 MNov 12, 2026
65ProShare Advisors LLC19,417-51 (-0.26%)0.01%$0 MOct 29, 2026
66Victory Capital Management Inc18,294+547 (+3.08%)0.01%$0 MNov 10, 2026
67Axxcess Wealth Management, LLC18,254New0.01%$0 MOct 21, 2026
68Principal Financial Group Inc18,154+6,769 (+59.46%)0.01%$0 MNov 2, 2026
69Osaic Holdings, Inc.17,292-5,000 (-22.43%)0.01%$0 MNov 12, 2026
70CIBC Bancorp USA Inc.15,289New0.01%$0 MNov 13, 2026
71Legal & General Group Plc14,5800 (0.00%)0.01%$0 MNov 16, 2026
72Accordant Advisory Group Inc14,3000 (0.00%)0.01%$0 MOct 29, 2026
73Crux Wealth Advisors14,250New0.01%$0 MNov 10, 2026
74Tower Research Capital LLC (TRC)14,222-5,489 (-27.85%)0.01%$0 MNov 16, 2026
75Centiva Capital, LP14,156-95,284 (-87.07%)0.01%$0 MNov 13, 2026
76Goldman Sachs Group Inc13,970-56,641 (-80.22%)0.01%$0 MNov 16, 2026
77Xponance LLC13,913-246 (-1.74%)0.01%$0 MNov 3, 2026
78One Wealth Management Investment & Advisory Services, LLC13,688New0.01%$0 MNov 16, 2026
79Creative Planning13,334-7,734 (-36.71%)0.01%$0 MNov 2, 2026
80Obermeyer Wealth Partners13,0000 (0.00%)0.01%$0 MOct 21, 2026
81AlphaCore Capital LLC12,380+2,205 (+21.67%)0.01%$0 MNov 4, 2026
82Ausdal Financial Partners, Inc.12,0750 (0.00%)0.01%$0 MNov 16, 2026
83Anchyra Partners LLC11,589New0.01%$0 MOct 13, 2026
84Waterloo Capital, L.P.11,484New0.01%$0 MNov 16, 2026
85Ieq Capital, LLC10,281-85,262 (-89.24%)0.01%$0 MNov 10, 2026
86HighTower Advisors, LLC10,012New0.00%$0 MNov 10, 2026
87Beacon Pointe Advisors, LLC10,0000 (0.00%)0.00%$0 MNov 16, 2026
88Farther Finance Advisors, LLC9,167+8,926 (+3703.73%)0.00%$0 MOct 8, 2026
89Citigroup Inc7,660-62,133 (-89.02%)0.00%$0 MNov 4, 2026
90Ameritas Investment Partners, Inc.7,0670 (0.00%)0.00%$0 MNov 13, 2026
91Sterling Capital Management LLC4,877+4,355 (+834.29%)0.00%$0 MOct 22, 2026
92FMR LLC2,605-1,610 (-38.20%)0.00%$0 MNov 10, 2026
93Optiver Holding B.V.1,436New0.00%$0 MNov 16, 2026
94California State Teachers Retirement System1,2630 (0.00%)0.00%$0 MNov 13, 2026
95Arax Advisory Partners1,169-8,824 (-88.30%)0.00%$0 MNov 12, 2026
96Jones Financial Companies Lllp1,0100 (0.00%)0.00%$0 MNov 13, 2026
97Winch Advisory Services, LLC8000 (0.00%)0.00%$0 MNov 6, 2026
98Robinhood Markets, Inc.500—0.00%$0 MNov 18, 2026
99GAMMA Investing LLC467+325 (+228.87%)0.00%$0 MOct 8, 2026
100Quaker Wealth Management, LLC3900 (0.00%)0.00%$0 MOct 22, 2026

All 116 institutional investors, with who bought and sold →

Mutual funds holding Lucid Diagnostics Inc.#

58 funds hold shares worth $22 M (about 10.2% of the company). Since their previous reports 42 added shares and 10 sold, buying $6 M net.
Mutual funds holding Lucid Diagnostics Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.4.55 M$5 M2.2%<0.01%+50%Jun 30, 2026
🇺🇸 abrdn Healthcare Opportunities Fundabrdn Inc.3.82 M$4 M1.8%0.50%+4.9%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors3.57 M$4 M1.7%<0.01%+62%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.1.86 M$2 M0.90%<0.01%+78%Jun 30, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors1.40 M$1 M0.67%<0.01%+291%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC1.58 M$1 M0.76%<0.01%+80%Jul 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors497,964$1 M0.24%0.04%+119%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC507,380$1 M0.25%<0.01%+1.7%May 31, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.459,876$0 M0.22%<0.01%+3.1%May 31, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.362,863$0 M0.18%<0.01%+84%Jul 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC277,964$0 M0.13%<0.01%+132%Jun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC171,254$0 M0.08%<0.01%no changeMay 31, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC195,065$0 M0.09%<0.01%+116%Jul 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC154,902$0 M0.07%<0.01%+109%Jun 30, 2026
🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC186,569$0 M0.09%0.02%−71%Jul 31, 2026
🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC138,850$0 M0.07%0.06%no changeJun 30, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC138,777$0 M0.07%<0.01%+362%Jun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC140,008$0 M0.07%<0.01%+8.2%May 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation113,100$0 M0.05%<0.01%+104%Jun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.91,840$0 M0.04%<0.01%+227%Jun 30, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.77,421$0 M0.04%<0.01%+59%Jun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC77,112$0 M0.04%<0.01%no changeMay 31, 2026
🇺🇸 AQR Small Cap Momentum Style FundAQR CAPITAL MANAGEMENT, LLC64,276$0 M0.03%0.04%—Mar 31, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC71,030$0 M0.03%<0.01%+79%Jul 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.56,088$0 M0.03%<0.01%+1.5%Jun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC43,087$0 M0.02%<0.01%+153%Jun 30, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.39,200$0 M0.02%<0.01%+54%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc.39,786$0 M0.02%<0.01%+4.7%May 31, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.35,295$0 M0.02%<0.01%+3.2%May 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC33,425$0 M0.02%0.02%+100%Jun 30, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company33,747$0 M0.02%<0.01%no changeMay 31, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC32,030$0 M0.02%<0.01%+112%Jun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS31,185$0 M0.02%<0.01%+158%Jun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC23,600$0 M0.01%<0.01%+113%Jun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC23,600$0 M0.01%<0.01%+113%Jun 30, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.23,419$0 M0.01%<0.01%+83%Jun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.22,417$0 M0.01%<0.01%+45%Jun 30, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC22,163$0 M0.01%<0.01%+309%Jun 30, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC20,448$0 M<0.01%<0.01%+149%Jun 30, 2026
🇺🇸 Gabelli Healthcare & WellnessRx TrustGabelli Funds, LLC19,500$0 M<0.01%0.01%no changeJun 30, 2026
🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC18,791$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.17,747$0 M<0.01%<0.01%+75%Jul 31, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC17,413$0 M<0.01%<0.01%+121%Jul 31, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC13,521$0 M<0.01%<0.01%+558%Jun 30, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC11,891$0 M<0.01%<0.01%+107%Jun 30, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS13,939$0 M<0.01%<0.01%+135%Jul 31, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.9,709$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC11,385$0 M<0.01%<0.01%+439%Jul 31, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC9,222$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management7,067$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC5,596$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC4,241$0 M<0.01%<0.01%+8.6%May 31, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC3,835$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC3,357$0 M<0.01%<0.01%−40%May 31, 2026
🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC3,317$0 M<0.01%<0.01%−41%May 31, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.2,755$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC2,141$0 M<0.01%<0.01%newMay 31, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.218$0 M<0.01%<0.01%+16%Jun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 58 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Lucid Diagnostics Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$245 K
1 purchase, 1 insider
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$245 K
open market only
Insiders on file
12
since
$458 K$0May 2025: bought $458 K (3 trades), sold $0 (0 trades)May 25Aug 2025: bought $102 K (1 trades), sold $0 (0 trades)AugMay 2026: bought $245 K (1 trades), sold $0 (0 trades)May
Bought (open market)Sold (open market)Hover a month for the totals
Lucid Diagnostics Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Dennis MatheisDirectorBuy+245,000$1.000$245 K1.03 MForm 4
filed Dennis MatheisDirectorGrant or award+123,000——788,443Form 4
filed Michael Adam GordonGeneral Counsel and SecretaryGrant or award+300,000——1.00 MForm 4
filed Stanley LapidusDirectorGrant or award10b5-1 plan+123,000——337,392Form 4
filed Shaun O'NeilPresident and COOGrant or award+620,000——1.45 MForm 4
filed Jacque J. SokolovDirectorGrant or award+123,000——320,460Form 4
filed Dennis M. McGrathChief Financial OfficerGrant or award+470,000——1.81 MForm 4
filed Debra WhiteDirectorGrant or award+123,000——235,800Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Lucid Diagnostics Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
15.0 M
11.4% of shares · 1 days to cover
Shares sold short, last 24 reportsAll stocks →

Fails to deliver

  • : 6,610 shares at $0.43
  • : 443,755 shares at $0.41
  • : 703,786 shares at $0.33
  • : 819,993 shares at $0.33
  • : 1.0 M shares at $0.35

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Lucid Diagnostics Inc. scorecard#

Passes 4 of the 15 checks that could be worked out: strongest in growth (3 of 4), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation0 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median8.1×Price to book 8.1× against Healthcare's median of 3.1×.
    • ✗Price to sales below its peers' median16.4×Price to sales 16.4× against Healthcare's median of 3.8×.
    • ✗Free cash flow yield above 5%-52.5%Free cash flow is -52.5% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth3 of 4
    • ✓Revenue grew in the newest year8.3%Revenue up 8.3% in fiscal 2025.
    • ✓Revenue up more than 5% a year over three years131.4%131.4% a year over the three years to fiscal 2025.
    • ✓Faster growth over three years than its peers' median131.4%131.4% a year against Healthcare's median of 8.5% (549 companies).
    • –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
    • ✗Net income higher than five years earlier-$58 M-$58 M in fiscal 2025 against -$8 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$58 MNet income -$58 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-710.5%-710.5% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities1.3×Current ratio 1.31 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-11.36Z-score -11.36 (distress zone) for fiscal 2025.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Healthcare, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Lucid Diagnostics Inc.'s statements, beside the median of Healthcare.

Lucid Diagnostics Inc.: main financial ratios in 2025
Ratio2025Median of peers
Return on equity-710.5%-36.9%
Revenue growth, 3 years a year131.4%8.5%
Revenue growth8.3%10.2%
Free cash flow margin-991.1%-1.3%

4of 8on the Piotroski tests of financial strength

  • Net loss of $58 million, the 6th loss-making year in a row.
  • Free cash flow was negative: -$47 million.
  • Receivables grew 1500% while revenue grew 8%: customers are paying later, or sales were booked ahead of cash.
  • Revenue has grown 3 years in a row.

Lucid Diagnostics Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Lucid Diagnostics Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020
Income statement
Revenue4.74.32.40.40.5—
Cost of revenue6.77.1—1000.6—
Gross profit———0.40.5r—
Research and development5.76.07.311r9.35.4
Selling, general and administrative————0.00.0
Selling and marketing181616165.31.3
General and administrative24201924r131.5
Operating expenses—505157r28r8.3
Total costs and expenses5450————
Operating income−50−46−48−56r−27−8.3
Interest and finance income0.40.3————
Interest expense and finance costs0.00.00.40.00.7—
Other non-operating income (expense)−8.40.5−4.20.1−0.7—
Income before tax−58−46−53−56−28−8.3
Income tax00————
Net income attributable to shareholders−58−46−53−56−28−8.3
Earnings per share, basic-0.69-1.05-1.26-1.55-1.51-0.59
Earnings per share, diluted—-1.05-1.26-1.55-1.51-0.59
Shares, weighted average (basic)10251423619—
Shares, weighted average (diluted)—5142361914
Balance sheet
Cash and cash equivalents35221922540.1r
Receivables0.60.00.00.00.2—
Inventory0.40.30.30.1——
Other current assets1.82.42.91.8r3.41.3r
Current assets37252224571.4r
Property, plant and equipment0.81.11.31.61.0—
Right-of-use (leased) assets1.82.61.32.0——
Other intangible assets0.30.71.43.4——
Total assets40312733592.2r
Accounts payable1.01.21.11.11.52.1r
Current liabilities2924298.44.3—
Lease liabilities (non-current)0.91.80.21.0——
Total liabilities3025309.54.316r
Retained earnings−274−204−151−98−42−14r
Shareholders' equity115.4−2.32355−14r
Total liabilities and equity40312733592.2r
Shares outstanding1316342413514
Cash-flow statement
Depreciation and amortization0.91.22.51.90.0—
Share-based compensation4.54.25.8149.1r0.1
Cash from operating activities−46−44−33−30−18−5.6
Capital expenditure−0.2−0.3—−3.2−0.9—
Intangible assets bought—−0.4————
Cash from investing activities−0.2−0.6−0.2−4.1−0.9—
Debt issued—————7.9
Debt repaid—−2.7————
Shares issued———1.8——
Cash from financing activities5948292.6725.6
Change in cash123.5−3.6−3154−0.0
Report10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Lucid Diagnostics Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Auditor changedFiling

Delisting notice 1 · Auditor changed 1 · Directors and officers 1 · Material agreement 7 · Agreement ended 1 · New debt 2 · Unregistered share sale 3 · Shareholder rights changed 3 · Bylaws or fiscal year changed 2 · Shareholder vote 2 · Results announced 9

Lucid Diagnostics Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Unregistered share saleShareholder rights changedBylaws or fiscal year changed8-K
Delisting notice8-K
Results announced8-K
Bylaws or fiscal year changedShareholder vote8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Material agreement8-K
Results announced8-K
Shareholder vote8-K
Material agreement8-K
Results announced8-K
Auditor changed8-K
Material agreement8-K
Results announced8-K
Material agreement8-K
Material agreementAgreement endedNew debtUnregistered share saleShareholder rights changed8-K
Material agreementNew debtUnregistered share saleShareholder rights changed8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of Lucid Diagnostics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2023$5 MPrivate placement after listing$2 to $10 million2equitySEC
Mar 2023$14 MPrivate placement after listing$10 to $50 million4equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Product recalls by Lucid Diagnostics Inc.#

1 recalls since 2015, 220 units in the notices that give a number. Medical devices (FDA): 1.

Lucid Diagnostics Inc.: product recalls
DateWhat and whyUnitsNotice
Brand Name: EsophaCap Product Name: EsophaCap (25mm diameter, 10 pores/inch) Model/Catalog Number: EC25T10VI Software Version: N/A Product Description: EsophaCap is pouched as individual units. 10 units go into a shelf-box. Component: N/A (and 1 more products)The EsophaCap sponge may be at increased risk of detaching from the string during removal of the device from the patient, particularly at the lower esophageal sphincter at the gastroesophageal junction or the upper esophageal sphincter between the pharynx and the esophagus, which is the narrowest part of the alimentary canal.Medical devicesClass II220Z-1900-2024

Source: NHTSA, CPSC and FDA recall notices. Recalls filed under a subsidiary with a different name may be missing. The number of recalls says nothing about their seriousness

How Lucid Diagnostics Inc. compares in Healthcare

  • Market cap$89 M · higher than 25% of 2,013
  • Revenue$5 M · higher than 18% of 1,795
  • Net margin-892.3% · higher than 1% of 1,485
  • Revenue growth8.3% · higher than 50% of 1,003
  • Price / sales16.4× · lower than 15% of 1,071
  • Price / book8.1× · lower than 18% of 1,245
  • FCF yield-52.5% · higher than 17% of 835
CompanyMarket capP/ENet marginRev. growth
Lucid Diagnostics Inc.🇺🇸$89 M—-892.3%+8.3%
Eli Lilly and Company🇺🇸$1.20 T43.4×31.9%+44.7%
Johnson & Johnson🇺🇸$652.5 B40.5×16.2%+6.0%
AbbVie Inc.🇺🇸$514.0 B49.7×15.7%+8.6%
Roche Holding AG🇨🇭$370.3 B29.1×19.0%—
UnitedHealth Group Incorporated🇺🇸$367.7 B23.1×3.5%+11.8%
Merck & Co., Inc.🇺🇸$359.8 B146.7×3.6%+1.3%
Novartis AG🇨🇭$286.8 B20.5×24.7%—
Thermo Fisher Scientific Inc.🇺🇸$253.8 B35.9×14.9%+3.9%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of March 23, 2026
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Lucid Diagnostics Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Lucid Diagnostics Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Lucid Diagnostics Inc.? Suggest a correction